Literature DB >> 21840418

The HDL proteome in acute coronary syndromes shifts to an inflammatory profile.

Khalid Alwaili1, Dana Bailey, Zuhier Awan, Swneke D Bailey, Isabelle Ruel, Anouar Hafiane, Larbi Krimbou, Sylvie Laboissiere, Jacques Genest.   

Abstract

Inflammation is a major factor underlying acute coronary syndromes (ACS). HDL particles may be remodeled, becoming functionally defective, under the inflammatory conditions seen in ACS. Shotgun proteomics was used to monitor changes in the HDL proteome between male age-matched control, stable CAD, and ACS subjects (n=10/group). HDL was isolated by ultracentrifugation and separated by 1D-gel followed by LC-MS/MS. We identified 67 HDL-associated proteins, 20 of which validated recently identified proteins including vitronectin and complement C4B, and 5 of which were novel. Using gene ontology analysis, we found that the HDL-proteome consisted of proteins involved in cholesterol homeostasis (~50%), with significant contributions by proteins involved in lipid binding, antioxidant, acute-phase response, immune response, and endopeptidase/protease inhibition. Importantly, levels of apoA-IV were significantly reduced in ACS patients, whereas levels of serum amyloid A (SAA) and complement C3 (C3) were significantly increased (spectral counting; t-test p≤0.05), as confirmed by immunoblot or ELISA. Despite differences in protein composition, ABCA1, ABCG1, and SR-BI mediated cholesterol efflux assays did not indicate that HDL from ACS patients is functionally deficient as compared to controls, when corrected for apoA-I mass. Our results support that the HDL proteome differs between control, CAD and ACS patients. Increased abundance of SAA, C3, and other inflammatory proteins in HDL from ACS patients suggests that HDL reflects a shift to an inflammatory profile which, in turn, might alter the protective effects of HDL on the atherosclerotic plaque. This article is part of a Special Issue entitled Advances in High Density Lipoprotein Formation and Metabolism: A Tribute to John F. Oram (1945-2010). Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840418     DOI: 10.1016/j.bbalip.2011.07.013

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  62 in total

1.  Proteome Dynamics Reveals Pro-Inflammatory Remodeling of Plasma Proteome in a Mouse Model of NAFLD.

Authors:  Ling Li; Gurkan Bebek; Stephen F Previs; Jonathan D Smith; Rovshan G Sadygov; Arthur J McCullough; Belinda Willard; Takhar Kasumov
Journal:  J Proteome Res       Date:  2016-08-05       Impact factor: 4.466

2.  Distinct Proteomic Signatures in 16 HDL (High-Density Lipoprotein) Subspecies.

Authors:  Jeremy D Furtado; Rain Yamamoto; John T Melchior; Allison B Andraski; Maria Gamez-Guerrero; Patrick Mulcahy; Zeling He; Tianxi Cai; W Sean Davidson; Frank M Sacks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-12       Impact factor: 8.311

Review 3.  HDL and cholesterol: life after the divorce?

Authors:  Kasey C Vickers; Alan T Remaley
Journal:  J Lipid Res       Date:  2013-03-19       Impact factor: 5.922

Review 4.  Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond.

Authors:  Amy S Shah; Lirong Tan; Jason Lu Long; W Sean Davidson
Journal:  J Lipid Res       Date:  2013-02-24       Impact factor: 5.922

5.  Restoration of renal function does not correct impairment of uremic HDL properties.

Authors:  Chantal Kopecky; Michael Haidinger; Ruth Birner-Grünberger; Barbara Darnhofer; Christopher C Kaltenecker; Gunther Marsche; Michael Holzer; Thomas Weichhart; Marlies Antlanger; Johannes J Kovarik; Johannes Werzowa; Manfred Hecking; Marcus D Säemann
Journal:  J Am Soc Nephrol       Date:  2014-07-28       Impact factor: 10.121

Review 6.  HDL dysfunction in diabetes: causes and possible treatments.

Authors:  Dan Farbstein; Andrew P Levy
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-03

Review 7.  HDL and endothelial protection.

Authors:  A Tran-Dinh; D Diallo; S Delbosc; L Maria Varela-Perez; Q B Dang; B Lapergue; E Burillo; J B Michel; A Levoye; J L Martin-Ventura; O Meilhac
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

Review 8.  Quantifying HDL proteins by mass spectrometry: how many proteins are there and what are their functions?

Authors:  Baohai Shao; Jay W Heinecke
Journal:  Expert Rev Proteomics       Date:  2017-11-13       Impact factor: 3.940

Review 9.  Dysfunctional HDL and atherosclerotic cardiovascular disease.

Authors:  Robert S Rosenson; H Bryan Brewer; Benjamin J Ansell; Philip Barter; M John Chapman; Jay W Heinecke; Anatol Kontush; Alan R Tall; Nancy R Webb
Journal:  Nat Rev Cardiol       Date:  2015-09-01       Impact factor: 32.419

10.  A Novel Medical Treatment for Lipid Control in Patients with Unstable Angina Pectoris and Statin-Induced Liver Dysfunction.

Authors:  Fang Cui; Youliang Zhang; Qingmin Wei; Cuihua Liu; Junhui Wang; Meng Zhang
Journal:  Acta Cardiol Sin       Date:  2015-01       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.